State Street Corp grew its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 1.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,208,875 shares of the medical instruments supplier's stock after purchasing an additional 208,811 shares during the period. State Street Corp owned about 5.52% of Becton, Dickinson and Company worth $2,722,389,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in BDX. BlackRock Inc. bought a new stake in shares of Becton, Dickinson and Company in the second quarter valued at about $3,721,533,000. First Eagle Investment Management LLC increased its stake in Becton, Dickinson and Company by 0.5% during the third quarter. First Eagle Investment Management LLC now owns 13,883,689 shares of the medical instruments supplier's stock valued at $2,485,180,000 after acquiring an additional 68,354 shares during the period. Bank of America Corp DE bought a new position in Becton, Dickinson and Company during the second quarter valued at about $474,993,000. Beutel Goodman & Co Ltd. raised its holdings in Becton, Dickinson and Company by 9.0% in the 3rd quarter. Beutel Goodman & Co Ltd. now owns 1,835,571 shares of the medical instruments supplier's stock valued at $328,567,000 after acquiring an additional 150,931 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Becton, Dickinson and Company by 1.5% in the 2nd quarter. Legal & General Group Plc now owns 2,101,695 shares of the medical instruments supplier's stock worth $318,050,000 after acquiring an additional 30,766 shares during the period. Institutional investors own 86.97% of the company's stock.
Analyst Ratings Changes
Several analysts have recently weighed in on the company. JPMorgan Chase & Co. lifted their price objective on Becton, Dickinson and Company from $170.00 to $202.00 and gave the stock a "neutral" rating in a report on Friday, November 6th. Wolfe Research assumed coverage on Becton, Dickinson and Company in a research note on Tuesday, October 20th. They issued an "outperform" rating for the company. TD Cowen boosted their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a "hold" rating in a report on Wednesday, August 5th. Jefferies Financial Group restated a "buy" rating and issued a $242.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, November 5th. Finally, Wells Fargo & Company increased their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an "equal weight" rating in a research note on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of "Hold" and a consensus target price of $197.47.
Check Out Our Latest Stock Analysis on BDX
Becton, Dickinson and Company Trading Down 0.2%
Shares of BDX opened at $212.19 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.54 and a debt-to-equity ratio of 0.54. The stock has a market cap of $58.47 billion, a PE ratio of 51.25, a PEG ratio of 3.56 and a beta of 0.22. Becton, Dickinson and Company has a 1 year low of $140.11 and a 1 year high of $220.36. The stock has a 50 day simple moving average of $194.40 and a 200-day simple moving average of $170.85.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, beating the consensus estimate of $4.07 by $0.08. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. The business had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.11 billion. During the same quarter in the previous year, the firm earned $3.96 EPS. Becton, Dickinson and Company's quarterly revenue was up 5.4% on a year-over-year basis. On average, sell-side analysts predict that Becton, Dickinson and Company will post 13.21 EPS for the current fiscal year.
Becton, Dickinson and Company Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be paid a $1.06 dividend. The ex-dividend date is Thursday, December 10th. This represents a $4.24 annualized dividend and a dividend yield of 2.0%. This is a boost from Becton, Dickinson and Company's previous quarterly dividend of $1.05. Becton, Dickinson and Company's dividend payout ratio is presently 101.45%.
Becton, Dickinson and Company declared that its board has initiated a share repurchase plan on Thursday, November 5th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to purchase up to 3.6% of its shares through open market purchases. Stock repurchase plans are often an indication that the company's board of directors believes its stock is undervalued.
Insider Activity
In related news, EVP Michael Feld sold 165 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. This trade represents a 0.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas Polen, Jr. sold 2,993 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $210.00, for a total transaction of $628,530.00. Following the sale, the chief executive officer owned 110,163 shares of the company's stock, valued at $23,134,230. This trade represents a 2.65% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 3,310 shares of company stock worth $688,650. 0.40% of the stock is owned by insiders.
Becton, Dickinson and Company Company Profile
(
Free Report)
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD's products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.